China Enteric Softgel Capsules Market

The China Enteric Softgel Capsules Market size is forecast to grow from approximately USD 0.485 Billion in 2025 to around USD 369.5Billion by 2035. According to Decision Advisors, a detailed research report on the enteric softgel capsules market indicates that the rapid expansion of nutraceutical and OTC supplement distribution through retail pharmacies, dominate the market, accounting for approximately 42% of the total share in the China. Sirio Pharma Co., Ltd. leads the market with an estimated 22% China market share. The company's annual revenue of approximately USD 80-100 million is making it one of the most influential forces shaping industry trends and overall market growth.

Market Snapshot

• China Enteric Softgel Capsules Market size (2025): USD 0.485 Billion
• Projected China Enteric Softgel Capsules Market Size (2035): USD 0.970 Billion
• China Enteric Softgel Capsules Market Compound Annual Growth Rate (CAGR): 7.18%
• Base Year: 2025
• Historical Period: 2021–2024
• Forecast Period: 2026–2035

Market Overview/Introduction

The China Enteric Softgel Capsules Market refers to the pharmaceutical and nutraceutical segment that develops capsules with enteric coatings, which protect against stomach acid to deliver medication directly into the intestine. The formulations improve product stability while increasing the bioavailability of sensitive active components, which include probiotics, enzymes, fish oils, and acid-labile drugs. China experiences rapid market growth because healthcare systems modernize, people develop a better understanding of digestive health, and dietary supplement usage grows. The market future depends on three factors, which include new developments in capsule shell technology, increasing interest in functional foods, and pharmaceutical companies outsourcing their work. Manufacturing plants within the country operate efficiently while healthcare reforms assist the industry in developing innovative softgel production methods.

• China has implemented continuous reforms in drug evaluation and approval through the National Medical Products Administration (NMPA). The system prioritizes innovative formulations such as enteric softgel capsules by accelerating clinical review, reducing approval timelines, and encouraging domestic production of advanced dosage forms. This improves market entry for high-value pharmaceutical and nutraceutical products, boosting industry expansion and technological upgrading.

• China has introduced industrial policies focusing on upgrading manufacturing standards, enforcing GMP compliance, and improving drug distribution efficiency. These measures encourage domestic production of high-quality softgel capsules while supporting foreign investment and technology transfer in pharmaceutical and nutraceutical sectors.

Notable Insights: -

1. The gelatin-based segment dominated the market in 2025 and holds the largest market share, accounting for approximately 55% during the forecast period.
2. The nutraceuticals segment dominated the market in 2025 and holds the largest market share, accounting for approximately 48% during the forecast period.
3. The retail pharmacies segment dominated the market in 2025 and holds the largest market share, accounting for approximately 42% during the forecast period.
4. The compound annual growth rate of the China Enteric Softgel Capsules Market is 7.18%.
5. The market is likely to achieve a valuation of USD 0.970Billion by 2035.

What is the role of technology in grooming the market?

Technology plays a critical role in the China enteric softgel capsules market by improving encapsulation efficiency, coating precision, and drug release control mechanisms. Advanced polymer coatings enable pH-sensitive release, ensuring targeted intestinal delivery and improved therapeutic outcomes. Automation in softgel manufacturing enhances production scalability and quality consistency. Nanotechnology integration improves bioavailability of poorly soluble drugs, while AI-driven quality control systems help detect formulation defects in real time. Additionally, continuous R&D in vegan capsule materials is expanding consumer acceptance. These technological advancements are significantly strengthening product innovation, manufacturing efficiency, and global competitiveness of China’s softgel industry.

Market Drivers

The China enteric softgel capsules market is driven by rising demand for advanced oral drug delivery systems that enhance absorption and reduce gastrointestinal irritation. Increasing prevalence of chronic diseases, digestive disorders, and nutritional deficiencies is boosting consumption of encapsulated formulations. Expanding nutraceutical demand, especially omega-3, probiotics, and herbal supplements, further supports growth. Strong pharmaceutical manufacturing infrastructure in China and increasing R&D investments are accelerating product innovation. Additionally, growing consumer preference for easy-to-swallow dosage forms and rising e-commerce penetration in healthcare products are strengthening overall market expansion across urban and semi-urban populations.

Restrain

The China enteric softgel capsules market faces challenges due to high manufacturing complexity, strict regulatory compliance requirements, and fluctuations in raw material prices such as gelatin and polymer coatings. Quality control challenges in maintaining uniform enteric coating performance also hinder production scalability. Regulatory approval timelines under NMPA can further delay product commercialization, impacting overall market entry speed for new formulations.

Study on the Supply, Demand, Distribution, and Market Environment of the China Enteric Softgel Capsules Market

The China enteric softgel capsules market exhibits a strong and expanding supply base supported by large-scale domestic pharmaceutical and nutraceutical manufacturers. Production is concentrated in industrial clusters with advanced GMP-compliant facilities. Demand is steadily increasing due to rising health awareness, an aging population, and a growing preference for preventive healthcare supplements. Distribution is diversified across hospital pharmacies, retail pharmacies, and rapidly expanding e-commerce platforms, which play a major role in supplement sales. The market environment is highly competitive, driven by innovation in formulation technology and increasing investments in functional food development. However, strict regulatory oversight and quality compliance requirements ensure controlled but stable market growth.

Price Analysis and Consumer Behaviour Analysis

Softgel capsule pricing in China varies depending on formulation complexity, coating technology, and active ingredient type. Enteric-coated variants are priced higher due to additional manufacturing processes and specialized excipients. Bulk pharmaceutical procurement keeps institutional pricing stable, while retail nutraceutical products show moderate variability based on brand positioning. Consumer behaviour is increasingly health-conscious, with strong preference for digestive-friendly and high-bioavailability supplements. Urban consumers dominate demand, driven by awareness of preventive healthcare. E-commerce platforms significantly influence purchasing decisions through product reviews, influencer marketing, and subscription-based wellness models, increasing repeat consumption patterns.

Market Segmentation

The China Enteric Softgel Capsules Market Share is classified into formulation type, application, and end user  

• The gelatin-based segment dominated the market in 2025 and holds the largest market share, accounting for approximately 55% during the forecast period.

Based on the formulation type, the enteric softgel capsules market is divided into gelatin-based and non-gelatin/vegan softgels. Among these, the gelatin-based segment dominated the market in 2025 and holds the largest market share, accounting for approximately 55% during the forecast period. The gelatin-based segment is driven by its cost-effectiveness, easy processing, and wide availability of raw materials. It offers strong film-forming properties, improved bioavailability, and high consumer acceptance. Established manufacturing infrastructure and compatibility with pharmaceutical formulations further strengthened its market share during the forecast period growth.

• The nutraceuticals segment dominated the market in 2025 and holds the largest market share, accounting for approximately 48% during the forecast period.

Based on the application, the enteric softgel capsules market is divided into pharmaceuticals, nutraceuticals, and dietary supplements. Among these, the nutraceuticals segment dominated the market in 2025 and holds the largest market share, accounting for approximately 48% during the forecast period. The nutraceuticals segment in the U.K. is attributed to rising consumer preference for preventive healthcare, dietary supplements, and wellness products. Increasing health awareness, aging population, and demand for convenient dosage forms like softgels further supported strong adoption, making nutraceutical applications hold the largest market share during the forecast period.

• The retail pharmacies segment dominated the market in 2025 and holds the largest market share, accounting for approximately 42% during the forecast period.

Based on the end user, the enteric softgel capsules market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. Among these, the retail pharmacies segment dominated the market in 2025 and holds the largest market share, accounting for approximately 42% during the forecast period. The retail pharmacies segment in the U.K. is driven by their wide accessibility, strong distribution network, and consumer preference for convenient medication purchase. Easy availability of prescription and OTC softgel products, along with trust in pharmacist guidance, further strengthened retail pharmacy sales, securing the largest market share during the forecast period.

Recent Development

• In March 2025, the China Enteric Softgel Capsules Market witnessed a strong shift toward Snutraceutical-driven demand, where personalized beauty and wellness softgels gained significant traction among consumers. This trend was fueled by rising health consciousness, preventive healthcare adoption, and increasing preference for convenient dosage forms delivering vitamins, omega-3, and herbal extracts.

• In February 2025, the China Enteric Softgel Capsules Market recorded significant advancements in enteric coating technology, focusing on improved drug stability and targeted intestinal release. Manufacturers increasingly adopted advanced polymer-based coatings that prevent degradation of active ingredients in the acidic stomach environment while ensuring precise release in the intestines.

Competitive Analysis

The report offers the appropriate analysis of the key organisations/companies involved within the China Enteric Softgel Capsules Market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

Top Key Companies in the China Enteric Softgel Capsules Market

• Catalent, Inc.
• Lonza Group Ltd.
• Sirio Pharma Co., Ltd.
• Aenova Group
• Thermo Fisher Scientific (Patheon)
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the China, regional, and country levels from 2020 to 2035. Decision Advisors has segmented the China Enteric Softgel Capsules Market based on the below-mentioned segments

China Enteric Softgel Capsules Market, By Formulation Type

• Gelatin-Based
• Non-Gelatin/Vegan Softgels

China Enteric Softgel Capsules Market, By Application

• Pharmaceuticals
• Nutraceuticals
• Dietary Supplements

China Enteric Softgel Capsules Market, By End User

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Frequently Asked Questions (FAQ)

Q. How is the supply chain structure evolving in China’s enteric softgel capsules industry?

A. The supply chain is becoming more integrated and localized, with manufacturers increasingly sourcing raw materials such as polymers, gelatin alternatives, and active pharmaceutical ingredients from domestic suppliers. At the same time, companies are investing in backward integration to reduce dependency on imports. Digital supply chain management systems are also improving inventory tracking and reducing production delays, making the overall ecosystem more resilient and cost-efficient.

Q. What impact is e-commerce having on the distribution of enteric softgel capsules in China?

A. E-commerce platforms are significantly reshaping product accessibility by enabling direct-to-consumer sales of nutraceutical and wellness softgels. Online channels have increased product visibility, especially among younger urban consumers who rely on reviews, influencer recommendations, and subscription models. This shift has reduced dependence on traditional pharmacy channels and increased competition among brands focusing on digital marketing strategies.

Q. Why is demand for vegan or non-gelatin softgel capsules increasing in China?

A. Demand for vegan or non-gelatin softgels is rising due to changing consumer preferences toward plant-based, halal-friendly, and allergen-free products. Health-conscious consumers are also seeking sustainable and ethically sourced alternatives to animal-derived gelatin. Additionally, advancements in plant-based polymers have improved capsule stability and performance, making them increasingly competitive with traditional gelatin-based formulations.

Q. How is China positioned in the global enteric softgel capsules market?

A. China is emerging as a key global manufacturing hub due to its strong pharmaceutical production infrastructure, cost advantages, and rapid technological adoption. The country is increasingly supplying both domestic and international nutraceutical and pharmaceutical companies with high-quality softgel formulations. Growing R&D investments and compliance with global GMP standards are further strengthening China’s export potential and competitiveness in international markets.